Polymorphism of Platelet Membrane Glycoprotein IIIa: Human Platelet Antigen 1b (HPA-1b/PlA2) Is an Inherited Risk Factor for Premature Myocardial Infarction in Coronary Artery Disease

Rainer B. Zotz; Bernhard R. Winkelmann; Markus Nauck; Günther Giers; Beate Maruhn-Debowski; Winfried März; Rüdiger E. Scharf

doi:10.1055/s-0037-1615054

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(04): 731-735
DOI: 10.1055/s-0037-1615054

Rapid Communication

Schattauer GmbH

Polymorphism of Platelet Membrane Glycoprotein IIIa: Human Platelet Antigen 1b (HPA-1b/Pl^A2) Is an Inherited Risk Factor for Premature Myocardial Infarction in Coronary Artery Disease

Rainer B. Zotz

¹From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany

,

Bernhard R. Winkelmann

²From the Department of Cardiology, Johann Wolfgang Goethe University Medical Center, Frankfurt, Germany

,

Markus Nauck

³From the Division of Clinical Chemistry, Albert Ludwigs University, Freiburg, Germany

,

Günther Giers

¹From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany

,

Beate Maruhn-Debowski

¹From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany

,

Winfried März

³From the Division of Clinical Chemistry, Albert Ludwigs University, Freiburg, Germany

,

Rüdiger E. Scharf

¹From the Department of Haemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf, Germany

› Author Affiliations

Abstract

Summary

Conflicting results of an association between the human platelet antigen 1b (HPA-1b or Pl^A2) allele and the risk of myocardial infarction and coronary artery disease have been reported. To assess the reason for this discrepancy, we determined the HPA-1 genotype in 298 men who had undergone coronary angiography, including 124 individuals with myocardial infarction, 83 individuals with coronary artery disease but no history of myocardial infarction, and 91 control patients. Among patients with acute or recent onset myocardial infarction (<1 year), the prevalence of HPA-1b was higher than among patients with coronary artery disease but without myocardial infarction (33 percent vs. 14 percent, p = 0.016). In patients under 60 years of age this difference was even more pronounced (45 percent vs. 15 percent, p = 0.003). Unlike conventional risk factors HPA-1b does not represent a risk factor for coronary artery disease itself but appears to be associated with increased platelet thrombogenicity.

Full Text

References

References
1 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986; 315: 983-9.
2 Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram. Quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986; 8: 1380-6.
3 DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-23.
4 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
5 Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
6 Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor. Haematologica 1992; 77: 162-8.
7 Nurden AT. Polymorphism of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995; 74: 345-51.
8 Scharf RE. Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Haemostaseologie 1996; 16: 114-38.
9 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
10 Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9.
11 Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991; 84: 708-11.
12 Verheut FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267-70.
13 The RISC Group.. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
14 Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia: the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992; 340: 497-501.
15 Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-5.
16 Klimt CR, Knatterud GL, Stamler J, Meier P, Persantine-Aspirin Reinfarction Study II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
17 Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab´)₂ fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
18 Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
19 Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab’)₂ antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393-405.
20 The EPIC Investigators.. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
21 Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley D, Worley SJ, Weisman HF, Califf RM, Topol EJ. for the EPIC investigators. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996; 28: 849-55.
22 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
23 Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386-404.
24 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
25 Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1071-2.
26 Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1072-3.
27 Ridker PM, Hennekens CH, Schmitz C, Stampfer M, Lindpaintner K. Pl^A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
28 Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-10.
29 Herrmann SM, Poirer O, Marques-Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The Leu³³/Pro polymorphism (Pl^A1/Pl^A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
30 Austen WG, Edwards JE, Frye RL, Gensini CG, Gott VL, Griffith LS. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51 Suppl 5-40.
31 Winkelmann BR, Nauck M, Klein B, Russ AP, Böhm BO, Siekmeier R, Ihnken K, Verho M, Groß W, März W. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996; 125: 19-25.
32 Zotz RB, Giers G, Maruhn-Debowski B, Scharf RE. Genetic typing of human platelet antigen 1 (HPA-1) by oligonucleotide ligation assay in a specific and reliable semi-automated system. Brit J Haematol 1997; 96: 198-203.
33 Nurden AT. Polymorphisms of the platelet receptors as risk factors in coronary thrombosis. Eur Heart J 1996; 17: 1293-1294.
34 Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.